WO2021055876A1
|
|
COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
|
WO2021022249A1
|
|
Fcrn antibodies and methods of use thereof
|
WO2020215021A1
|
|
Sialylated glycoproteins
|
WO2020142275A1
|
|
Methods of producing ustekinumab
|
WO2020077298A1
|
|
Treatment with highly silylated igg compositions
|
WO2020051042A1
|
|
Methods of continuous cell culture
|
US2020110095A1
|
|
Methods of protein interaction analysis
|
AU2019312139A1
|
|
Compositions of FcRn antibodies and methods of use thereof
|
SG11202100419UA
|
|
Fcrn antibody compositions
|
WO2020014542A2
|
|
Compositions and methods related to engineered fc-antigen binding domain constructs
|
AU2019300020A1
|
|
Compositions and methods related to engineered Fc-antigen binding domain constructs
|
CA3106108A1
|
|
Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
|
WO2020014526A2
|
|
Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
|
WO2020014486A1
|
|
Compositions and methods related to engineered fc-antigen binding domain constructs
|
WO2020014505A2
|
|
COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
|
CA3106207A1
|
|
Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
|
CA3105985A1
|
|
Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
|
WO2019210306A1
|
|
Blood preparation
|
WO2019118791A1
|
|
Fcrn antibodies and methods of use thereof
|
WO2019060330A1
|
|
Methods for predicting response to treatment
|